In Vitro Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Clinical Isolates of Meropenem-Non-Susceptible Pseudomonas aeruginosa: A Two-Center Study.
Our objective was to compare the activity of ceftazidime-avibactam (C/A), ceftolozane-tazobactam (C/T) and 3 anti-pseudomonal beta-lactams (piperacillin-tazobactam, ceftazidime, cefepime) against a collection of meropenem-non-susceptible P. aeruginosa clinical isolates recovered from two centers in Turkey. A total of 102 unique patient isolates of meropenem-non-susceptible P. aeruginosa were included in the study. MICs of antimicrobials were determined by gradient diffusion method. Overall susceptibility rates for C/A and C/T were 83.3% and 82.4%, respectively. Both C/A and C/T had better activity than any one of the 3 anti-pseudomonal beta-lactams. According to MIC50 values, C/T was the most potent agent against isolates. Although the susceptibility rates of isolates to C/T and C/A were similar, C/T (MIC50, 1 μg/mL) was 4-fold more potent than C/A (MIC50, 4 μg/mL). The MIC50 values of C/A and C/T for the isolates that were non-susceptible to 3 beta-lactams were significantly higher than those for isolates that were non-susceptible to 0, 1 or 2 beta-lactams. Also, C/A MIC50 value for the isolates that were non-susceptible to 2 beta-lactams was higher than that for isolates which were non-susceptible to 1 beta-lactam. C/A and C/T showed good activity against meropenem-non-susceptible P. aeruginosa isolates. However, resistance to these agents was not rare among these isolates. Overall beta-lactam susceptibility profile of isolates seems to have an effect on the probability of susceptibility to C/A and C/T. Antimicrobial susceptibility testing should be performed for C/A and C/T, if these agents are considered for treatment of infections caused by meropenem-non-susceptible P. aeruginosa.